ObsEva racks up $60 mln Series B
Swiss biopharmaceutical company ObsEva, a developer of drugs that focus on "serious conditions compromising pregnancy from conception to birth," has raised $60 million in Series B funding. The investors included HBM Healthcare Investments, New Enterprise Associates, OrbiMed, Rock Springs Capital, Sofinnova Partners, Sofinnova Ventures, Novo Ventures and MS Ventures. In addition to the funding, Ed Mathers of NEA has been added to ObsEva's board of directors. Leerink Partners LLC was the advisor on the funding.
23 November 2015•3 mins read
